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Background: Cancer chemoprevention is considered one of the most promising areas in current cancer research,
and asiaticoside, which is derived from the plant Centella asiatica, has a relative lack of systemic toxicity. The
purpose of this study was to investigate whether asiaticoside is effective against 7,12-dimethylbenz(a)anthracene
(DMBA)-induced carcinogenicity in vitro (MCF-7 and other cells) and in vivo (DMBA-induced rat cancer).
Methods: An MTT assay was performed involving the treatment of MCF-7 cells for 48 h with H2O2 alone and
H2O2 + different asiaticoside concentrations. Flow cytometry was performed, and the level of caspase 3, tumour
necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) were quantified. Adult female Sprague–Dawley (SD) rats were
divided into five groups designated I (control), II (DMBA-induced cancer), III (pre- and post-treatment with asiaticoside
(200 μg/animal) in DMBA-induced cancer), IV (post-treatment with asiaticoside in DMBA-induced cancer), and V
(treated with asiaticoside alone, drug control). Twelve weeks post-DMBA, rats developed mammary tumours. Rats
either were sacrificed or imaged with MIBI. Histological examination of tumour tissues was performed. Tumour MIBI
uptake ratios were determined. The data are expressed as the means ± standard deviation. Appropriate t-test and
ANOVA statistical methods were used to compare data.
Results: The IC50 of asiaticoside for MCF-7 cells was determined to be 40 μM. Asiaticoside has potential for hydrogen
peroxide cytotoxicity, and the caspase-3 activity increased with increasing asiaticoside dose in MCF-7 cells treated for
48 h. The expression of the cytokines TNF-α and IL-1β was significantly decreased and correlated with MIBI uptake ratios
in vitro and in vivo after asiaticoside administration.
Conclusion: This study demonstrates that asiaticoside is effective in vitro and in vivo in inducing apoptosis and
enhancing anti-tumour activity.
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According to the American Cancer Society, more than
7.6 million people die from cancer in the world each year
[1], and cancer chemoprevention using different drugs
and natural agents has been attempted. Centella asiatica
is a plant that is widely used in traditional Ayurvedic
medicine for a variety of illnesses. Recent research has
shown that components of Centella asiatica, particularly
asiaticoside, show great pharmacological effects in the pre-
vention and treatment of cancer [2], ulcers [3] diarrhea,
asthma, tuberculosis, various skin lesions, wound healingCorrespondence: fatimas@hsc.edu.kw
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reproduction in any medium, provided the or[4,5], mental disorders [6], and atherosclerosis, as well as a
fungicidal antibacterial [7], and antioxidant effects [8,9].
7,12-Dimethylbenz(a)anthracene (DMBA)-induced rat
mammary cancer has been widely exploited in cancer
studies for many years [10-12]. In this study, we applied
our asiaticoside treatment system to a DMBA-induced
rat mammary cancer model and human breast cancer
(MCF-7) cells.
Technetium-99 m hexakis-2-methoxyisobutylisonitrile,
Tc-99 m-sestamibi (99mTc-MIBI) is a cationic lipophilic
radiopharmaceutical commonly used in nuclear cardiology
that has been reported to be used in several tumour types
including those of the breast, lung, thyroid, brain, head
and neck, gastrointestinal tract, solid tumours of bones
and soft tissues and lymphomas [13-16]. The human. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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it is a commonly available human breast cancer in vitro
model. MCF-7 cells have been previously studied using
MIBI and have shown high MIBI uptake after 60 min in
comparison with other types of cancer cell lines [17-19].
Few studies in the literature investigated the asiatico-
side effects on cancer, and the effects of asiaticoside in
tumours are limited. In this study, the asiaticoside effects
in vitro on cancer cells and in vivo on DMBA-induced
carcinogenesis in rats were investigated via radionuclide
imaging and various molecular biology tests.
Methods
Materials
MIBI or sestamibi (cardiolite) were purchased from Bristol-
Myers Squibb (New York, USA). The pertechnetate (99mT
cO−4) radionuclide was obtained from a molybdenum-
99-technetium-99 m (99Mo-99mTc) generator purchased
from Amersham International plc (Amersham, UK). 7,12-
Dimethyl benzanthracene (DMBA), asiaticoside (MW=
959.12) and all other reagents used in this study were
supplied by Sigma-Aldrich (UK). Propidium iodide (PI)-
ribonuclease (RNase) staining buffer (BD staining kit)
was obtained from BD Biosciences.
The approval of an appropriate ethics committee
All experimental research reported in this manuscript was
approved by the Kuwait University Faculty of Medicine
scientific local ethics committee.
Cell culture and media
All of the culture media and supplements were provided by
Biowhittaker (Fisher Scientific., Ratastie, Finland, Europe).
The human breast cancer MCF-7, MDA-231, pII and HBL-
100 cell lines, the prostate cancer PC-3 cell line and the
human keratinocyte skin HaCaT cell line were purchased
from Cell Lines Service (Eppelheim, Germany) between
March and June 2012. MCF-7 cells were grown in ad-
vanced Dulbecco’s Modified Eagle Medium (Advanced
DMEM) supplemented with 10% foetal calf serum (FCS),
2 mmol/l L-glutamine, 100 units per ml penicillin and
100 mg/ml streptomycin and incubated in a humidified
atmosphere with 5% CO2: 95% air at 37°C. Unless other-
wise stated, stock cultures of MCF-7 cells were seeded at a
density of 2 × 105 cells/ml in 25 cm2 flasks and allowed to
multiply for 48 to 72 h. For chemotherapy experiments,
the MCF-7 cells were drug-sensitive/wild type (WT) cells
and allowed to grow exponentially to 70% confluency.
Cells were cultured in two groups: MCF-7 cells alone
(control) and MCF-7 cells treated with different asiatico-
side concentrations for 24, 48, or 72 h (treated cells). All
cells were tested and authenticated in March 2011 and
again tested in June 2012.In vitro experimental studies
Cell viability (MTT) assay
MCF-7 cells (1 × 106) were incubated in 25 cm2 flasks in
triplicate. The flasks were set up for controls and differ-
ent asiaticoside concentrations (0.0025, 0.01, 0.02, 0.04,
0.1, 0.2, 0.25, 0.3, 0.5, 1, 10, 20, 40, 50, 125, 250 and
500 μM) and then incubated in a humidified atmosphere
with 5% CO2: 95% air at 37°C for different time points
(24, 48 and 72 h). Measurement of cell viability was
determined using the 3-(4–5 dimethylthiozol-2-yl)-2,5
diphenyl-tetrazolium bromide (MTT) assay, which is
based on the conversion of MTT to MTT-formazan by
mitochondria.
In addition, in some experiments, MCF-7 cells and
pII, PC-3, MDA-231 and HBL-100 cells were seeded in
flat-bottomed 96-well tissue culture plates in triplicate at
a concentration of 1 × 105 cells/ml medium in a volume
of 100 μl per well and allowed to grow to 70% con-
fluency before the addition of asiaticoside. After reaching
70% confluency, different concentrations of asiaticoside
(0, 0.0025, 0.25, 0.5, 1, 20, 40, and 80 μМ) was separately
added and incubated for 24, 48 and 72 h. After the incu-
bation period, the medium was removed, the cells were
washed with phosphate buffered saline (PBS), and 100 μl
fresh medium was then added together with 20 μl of
MTT (5 mg/ml) to each well. The plates were protected
from light and incubated for 3 h, and the formazan crystals
formed were solubilised with 200 μl dimethyl sulphoxide
(DMSO). The plates were maintained in a shaker with
gentle mixing for 20 min to dissolve the precipitate. The
colour developed was measured in a 96-well plate scan-
ner (Multiskan Spectrum, Thermo Electron Corporation,
Vantaa, Finland) at dual filter wavelengths of 540 and
690 nm. The cell viability was expressed as percentage
over the control. This viability test was used to determine
the optimum asiaticoside inhibitory concentration (IC50)
for MCF-7 cells.
MTT experiment with hydrogen peroxide (H2O2)
MCF-7 cells were cultured in 96-well plates (1 × 106
cells per well) in triplicate and then incubated in a hu-
midified atmosphere with 5% CO2: 95% air at 37°C.
The 96-well plates were prepared for experiments in-
volving H2O2 alone and different asiaticoside concen-
trations + H2O2.
For H2O2 alone, the media was aspirated, the wells
were washed with PBS, and different concentrations of
H2O2 diluted in 1% serum media were then added to the
wells: 0, 0.025, 0.05, 0.1, 0.2, 0.3, 0.5 and 1 mΜ.
For H2O2 + asiaticoside, 1 μΜ asiaticoside was added
and incubated for 2 h. The media was aspirated, a combin-
ation of 1 mΜ H2O2 and 1 μΜ asiaticoside was added, and
the cells were incubated overnight. After 24 h, the MTT
assay was performed as described above.
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A total of 1 × 106 MCF-7 cells/ml were seeded in a 25 cm2
tissue culture flask to determine the DNA synthesis phase
(S phase) by 2-dimensional (2D) flow cytometry analysis.
Cells were treated with different concentrations of asiati-
coside e.g., 0, 20, 40, and 80 μМ, and incubated for 48 h.
Cells were washed twice in ice-cold PBS, harvested with
0.5% trypsin, and centrifuged. The pellets were resus-
pended in 5 ml of ice-cold 70% ethanol while vortexing.
These resuspended cells were maintained at −20°C over-
night. The samples were centrifuged and washed with
2 ml PBS, the samples were centrifuged again and then
1.2 μl RNAase was added. The samples were vortexed and
incubated in a water bath at 37°C for 15 min. After the in-
cubation period, 200 μl propidium iodide was added, and
the cells were then mixed well and transferred to a FACS
tube. Analysis was performed using a Beckman Coulter
Cytomics FC 500 (Miami, FL, USA).
Assessment of DNA damage
DNA damage was assessed using the cell-death detection
ELISA procedure described below.
Cell death detection, enzyme-linked immunosorbent assay
(ELISA) procedure
MCF-7 cells were cultured in 6-well plates (2 × 105 cells
per well) in triplicate and washed with PBS; different
concentrations of asiaticoside dissolved in 1% serum media
(0, 50, 100 and 200 μМ) was added, and then the cells were
incubated for 48 h.
A total of 100 μl coating solution was added into each
well of the MP-module and incubated for 1 h at 15–25°C.
The coating solution was thoroughly removed by tapping
or suctioning. A total of 200 μl incubation buffer was
added into each well of the MP-module and incubated for
30 min at 15–25°C. The wells were washed with 250–
300 μl per well washing solution 3 times, and the washing
solution was carefully removed. A total of 100 μl of
sample solution was added into each well of the MP-
module. The solution was thoroughly removed by tapping
or suctioning. The wells were washed with 250–300 μl per
well washing solution 3 times, and the washing solution
was carefully removed. A total of 100 μl of substrate solu-
tion was added into each well of the MP-module and in-
cubated on a plate shaker at 250 rpm until the colour
development was sufficient for photometric analysis (ap-
proximately 10–20 min). The contents of the wells were
then homogenised by careful tapping at the MP-module
edges, and the plates were measured at 405 nm against
substrate solution as blank.
Apoptosis
MCF-7 cells were plated in 6-well plates (1×106 cells/well)
overnight. The following day, the cells were washed withPBS, and 1 ml RPMI media without foetal bovine serum
(FBS) was added and incubated overnight. Different con-
centrations of asiaticoside (0, 0.5, 1, 50, 125, 250, 500 μM)
were added and incubated for a 24, 48, or 72 h incubation
period. Apoptosis assays were performed by trypsinising
MCF-7 cells and centrifuging the cells together with the
aspirated media. Cell pellets were washed twice with ice-
cold PBS. A total of 10 μl Annexin V-PE and 100 μl 1X
binding buffer was added to the pellet in a 15 ml centri-
fuge tube and incubated for 15 min on ice in the dark.
After incubation, 10 μl 7AAD was added with 380 μl 1X
binding buffer, making the total volume of 500 μl. The ‘0’
concentration (control) was labelled as reference, and
500 μl 1X binding buffer was added without Annexin V-
PE and 7AAD. All content in the tubes was transferred to
10 ml glass tubes, and an apoptotic assay was then per-
formed using flow cytometry (Beckman Coulter Cytomics
FC 500, France).
Apoptosis markers
The levels of caspases 3 and 9 were estimated in treated
MCF-7 cells in comparison with controls. The levels of
p53, NF-kB, phosphoinositide-3 kinase (PI3K), Bcl2 and
Bcl2 family proteins (Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim
and Hrk) were determined and assayed. TRAIL receptors-
1 and 2 (TRAIL-R1 and TRAIL-R2), death receptors 3, 4,
and 5 (DR3, DR4 and DR5) and tumour necrosis factor
(TNF) superfamily Fas associated death domain were
quantified by western blot analysis. This analysis was per-
formed to determine the pathway through which the cells
undergo apoptosis. The determination of cell cycle phase
by flow cytometry was to determine whether the cells
were undergoing apoptosis.
Western blot
MCF-7 cells were cultured in 25 cm flasks and incu-
bated in a humidified atmosphere with 5% CO2: 95% air
at 37°C until reaching 70% confluency. The plates were
set up in triplicate for controls and asiaticoside-treated
cells. The asiaticoside concentration used was the deter-
mined IC50 (40 μΜ), and the cells were incubated for
48 h. After incubation, the cells were gently resuspended
in 75 μL RIPA buffer and incubated on ice for 30 min.
The cells were then centrifuged for 10 min at 10,000 × g
and 4°C. Supernatant representing the total cell lysate
was maintained at −80°C. The protein concentration of
the sample was determined with an Ultrospec 2100 pro
UV/Visible Spectrophotometer (GE Healthcare, USA).
The extracted protein was quantified with a BCA pro-
tein assay. Protein levels were evaluated by densitometry
using a GS-800 Calibrated Imaging Densitometer (Bio-
Rad Laboratories, USA).
Protein samples (30 μg) were resolved in a 12% sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
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placed in a 3% 50 ml blocking solution in a clean petri
dish for 1 h with gentle shaking. After blocking, the mem-
brane was washed in PBS and probed with a primary anti-
body for 1 h at room temperature. After incubation, the
membrane was washed 3 times with a 20% Tween 20 1×
PBS solution and then probed with a secondary antibody
for 1 h with shaking, then placed in a developing solution.
Caspase-3 fluorescence ELISA assay
MCF-7 cells (1 × 106 cells/well) in 2 ml of culture medium
were seeded in 6-well plates in triplicate. The following
day, the cells were treated with different concentrations of
asiaticoside, 0, 50, 100, and 200 μМ, and incubated at 37°C
for 48 h. The plates were centrifuged at 800 × g for 5 min,
the culture medium was aspirated and 200 μl of caspase-3
assay buffer was added to each well. A total of 100 μl cell
based assay lysis buffer was added to each well, and the
plates were incubated with gentle shaking on an orbital
shaker for 30 min at room temperature. The plates were
centrifuged at 800 × g for 10 min, and 90 μl of the super-
natant from each well was transferred to a corresponding
well in a new black 96-well plate. Next, 10 μl of caspase-3
inhibitor solution was added to the appropriate wells in
the black plate, and 100 μl of active caspase-3 standard
was also added to wells in the same Plate. A total of 100 μl
caspase-3 substrate solution was added to each well, the
plates were incubated at 37°C for 30 min and the fluores-
cent intensity of each well was simultaneously measured at
an excitation window of 485 to 535 nm.
Immunostimulation effects of asiaticoside
The immunostimulation of the asiaticoside was tested
in cancer-induced rats. The mRNA expression of the
complement components platelet activating factor (PAF),
cyclooxygenases 1 and 2 (COX1 and COX2), tumour ne-
crosis factor-alpha (TNF-α) and interleukin-1 (IL-1) was
studied using reverse transcription-polymerase chain reac-
tion (RT-PCR). This assay helps to determine whether
asiaticoside mediates or inhibits inflammation.
RNA extraction and real-time PCR (RT-PCR)
A total of 500 μl TRIzol reagent was added to frozen cell
pellets or tissue samples; these mixtures were homogenised,
and 100 μl chloroform was added. The RNA remained ex-
clusively in the aqueous phase. The aqueous phase was
transferred into a fresh tube, and the RNA from the aque-
ous phase was precipitated by mixing with 500 μl iso-
propanol and incubating at −20°C overnight. The RNA
pellet was washed twice with 500 μl cold 70% ethanol,
was dissolved in 25 μl RNAse-free water and incubated
for 10 min at 60°C. The purity and yield of the RNA was
quantified by measuring the absorbance of the RNA so-
lution at 260 and 280 nm.The extracted RNA was normalised to 500 ng and
converted to cDNA using the high capacity cDNA reverse
transcription kit (Applied Biosystems, California, USA).
DNase treatment of RNA samples prior to RT-PCR was
performed according to the manufacturer’s instructions.
RT-PCR for the converted cDNA was performed using
the Taqman Fast reagent starter kit (Applied Biosystems,
California, USA) with an Applied Biosystems 7500 Real-
Time PCR System (Applied Biosystems, California, USA).
Global gene expression analysis was performed (data not
shown), and some well-known candidate genes were se-
lected and investigated, including Bcl2 and Bcl2 family
proteins (Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim and Hrk),
COX-1, COX-2, IL-1, and TNF-α.
In vivo experimental studies
Experimental animals
Adult female Sprague–Dawley (SD) rats (250 ± 50 g body
weight, 8 weeks age) bred at the Animal Facility of the Fac-
ulty of Medicine, Kuwait University, were used in this study
(total n = 20). The animals had free access to water and
food and were housed 4–5 rats per cage and maintained at
23 ± 2°C in a 12 h light:dark cycle. The animals were han-
dled in accordance with an established animal use protocol
following the recommendations of the Kuwait University’s
institutional animal care and use committee (IACUC).
Experimental protocol
SD rats were randomly divided into five different groups
(Figure 1), and experiments were performed accordingly
with each consisting of 15 inbred SD rats designated I, II,
III, IV, and V. Group I served as normal control animals
and were given sesame oil from the 1st to 11th week via
oesophageal intubation. Group II represented tumour-
bearing rats. In this group, tumours were induced in the
3rd week by a single dose of 0.5 ml DMBA (10 mg/animal)
in sesame oil administered via oesophageal intubation, and
the rats were given only oil (1–2 and 4–11 weeks) in the
subsequent weeks. Group III animals were subjected to
pre- and post- treatment with asiaticoside (200 μg/animal)
given intraperitoneally (ip) at 1–2 and 4–11 weeks each
twice, and tumours were induced in the 3rd week. Group
IV animals were treated with a similar dose of asiaticoside
from week 7, and DMBA was induced in the 3rd week.
Group V animals were treated with asiaticoside alone (drug
control). Animals were palpated weekly for tumour forma-
tion. At 12 weeks post-DMBA exposure, all animals were
sacrificed. At this time, all tumours, skin and visceral or-
gans were saved by snap freezing in liquid nitrogen and
then stored at −80°C for further molecular analysis.
Weight gain and tumour development
The animal body weight in grams was recorded every three
weeks. The weight homogeneity index (HI) was calculated
Figure 1 The experimental protocol.
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HI =Wl/(Wl +Wh)/2, where Wl is the lowest weight
and Wh is the highest weight found in all groups. In
addition, body weight gain (Wg) in grams was calculated
according to the formula Wg = (Wx-W0)/W0*100, which
considers the weight recorded in the beginning (W0)
and at the end (Wx) of the study. All animals were mon-
itored for tumour development. The tumour mass was
measured horizontally and vertically using a calliper.
The tumour volume (V) was calculated according to the
formula V = (a(b)2)/2, where ‘a’ and ‘b’ are the longest
and shortest diameters of the tumour, respectively, as
described in Carlsson et al. [20].Preparation of 99mTc-MIBI (MIBI)
Lyophilised MIBI vial products were reconstituted using
1110 MBq of fresh 99mTcO−4. The vials were heated in a
boiling water bath for 10 min. Quality control procedures
were performed according to the manufacturer’s instruc-
tions after cooling in room temperature using Whatman-1
paper and chloroform:methanol solution (75:25). An MIBI
labelling efficiency greater than 95% was used.MIBI tumour uptake imaging and processing
The rats in each group were anaesthetised using an intra-
peritoneal (ip) injection of ketamine: xylazine (40 mg/kg:
5 mg/kg body weight; Serumwerk, Bernburg, Germany)
injected with 37 MBq MIBI and imaged in two dynamic
phases: a vascular phase at 1 sec/frame for 1 min and a
subsequent parenchymal phase at 1 min/frame for 1 h.Images were visualised in a 0–61 min composite image.
The regional distribution of MIBI was determined by
drawing a region of interest (ROI) over tumours and other
vital organs such as the heart, liver, spleen, bladder and
whole body (WB). The tumour to WB ratio for MIBI be-
fore DMBA (control) and after DMBA or asiaticoside ad-
ministration was obtained.
Apoptosis markers and apoptosis analysis by flow
cytometry and RT-PCR
These assays were performed as described above in vivo
in rats with DMBA-induced mammary carcinogenesis
treated with asiaticoside in comparison with controls.
Presentation of data and statistical analysis
Unless otherwise stated, all data are expressed as the
means ± standard deviation (means ± SD). Student’s t-test
was used to determine significant differences between two
means, while Kruskal-Wallis non-parametric analysis of
the one-way analysis of variance (ANOVA) test was used
to evaluate differences between study groups. Statistical
analysis was performed using SPSS version 17.0 software
(Chicago, USA).
Results
Cell viability (MTT) assay
The viability, which was expressed as the percentage of
inhibition over control for MCF-7 cells for 24, 48, and
72 h, was obtained with an MTT assay. The IC50 value
of asiaticoside for MCF-7 cells was detected, and it was
determined to be 40 μM at 48 h. As described above in
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different concentrations of asiaticoside for 24, 48, and
72 h in different cell lines (MCF-7, MDA-231 and HBL-
100, PC-3 and pII) using the MTT assay. The results dem-
onstrated that asiaticoside had no effect on the cell lines
at these concentrations with the exception of the MCF-7
cells (Figure 2).
MTT experiments with H2O2
Figure 3 shows the percentage of cell inhibition over
control for a 48 h incubation period and the asiaticoside
potential for the cytotoxicity of hydrogen peroxide using
an MTT assay with MCF-7 cells. The use of H2O2 in the
MTT experiment was to induce oxidative stress, apoptosis
and cytotoxicity. Asiaticoside does not cause genotoxic
effects in cell lines.
Assessment of DNA damage, cell death detection, ELISA
and caspase-3 fluorescence
Figure 4 shows the percentage of fragmented DNA and
cell death in response to the effects of asiaticoside ad-
ministration in MCF-7 cells as detected by ELISA. The
percentage of cell death (inhibition) increases with asia-
ticoside concentration. In addition, cell death was de-
tected using a caspase-3 fluorescence assay. Asiaticoside
downregulated the expression and activity of caspase-3
(Figure 5).
DNA synthesis and apoptosis marker measurement by
flow cytometry
DNA synthesis (S phase) and apoptosis were measured by
flow cytometry. Histograms were generated to determine
the cell cycle phase distribution after debris exclusion.Figure 2 Raw data for the percentage of cell inhibition for a 48 h asia
cell lines with the exception of the MCF-7 cell line upon MTT assay.The sub-G1/G0 peaks were considered to be representa-
tive of apoptotic cells, and the S histogram bars were
representative of DNA synthesis phase cells. S phase
values were highly significantly higher at all concentra-
tions (0, 20, 40, and 80 μm asiaticoside) compared with
other cell cycle phases, and there were significant differ-
ences at 40 μm as compared with other concentrations
and control (Figure 6).
Determination of in vitro and in vivo mRNA expression
by RT-PCR
The results showed that asiaticoside has an effect on cyto-
kinin expression in DMBA-bearing tumours (Figure 7)
as well as in MCF-7 cells. Asiaticoside led to decreased
tumour necrosis factor-alpha (TNF-α) and interleukin-1
beta (IL-1β) expression. Asiaticoside affected neither pro-
apoptotic Bax nor anti-apoptotic Bcl-2 expression.
In vivo animal imaging
Weight gain and tumour development
Animals from each group were healthy, and after the 8th
week of experiments, tumours were mostly observed in
groups II, III, and IV. The developed tumours were soft,
rubbery and more adherent to the skin than the body
wall (Figure 8). In 15 rats, multiple tumour growths were
observed at 1–4 sites in the body, including tumours in
the left and right thoracic chest (C) and the femoral site
(F) for groups II, III, and IV (rats receiving DMBA).
Without treatment, DMBA-induced tumours grew rap-
idly but did not metastasise.
The weight of the animals for all groups was similar as
indicated by the homogeneity index. The animal body
weight (mean gain ± SD) in grams was determined everyticoside incubation period, showing no effects of asiaticoside on
Figure 3 The percentage of asiaticoside cell inhibition over control for a 48 h incubation period and the potential for hydrogen
peroxide cytotoxicity using an MTT assay for MCF-7 cells.
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(Table 1). The mean weight progressively increased dur-
ing the study.
After 12 weeks of the study, groups II, III, and IV (rats
receiving DMBA) showed 5.8, 6.2, and 5.2% less body
weight compared with group I. In other words, rats not
receiving DMBA (controls) were 5-7% heavier than rats
receiving DMBA. No significant difference (p < 0.05) was
found between group I (control) and group II (tumour
bearing rats).
Results showed a tumour volume increase on a weekly
basis beginning with the 8th week, which is presented in
graphic form in Figure 9. The tumour volume was calcu-
lated by multiplying the length of the tumour by the
square of the width and dividing the product by two. To
obtain statistically significant results, the experimental
groups were repeated.
The results showed that rat tumours from groups III
and IV (treated with asiaticoside) showed significant lessFigure 4 Percentage of fragmented DNA in response to the effects oftumour progression (p < 0.001) as compared to group II
(positive control, Figure 9).
In addition, rat tumours from groups II, III, and IV
were grounded into powder to perform further studies.
RNA and protein extraction was then performed accord-
ing to the procedure described above. Western blotting
and RT-PCR was performed from these samples.
MIBI radiotracer in vitro uptake determination
In some experiments, in vitro MIBI uptake in MCF-7 cells
was detected as described in Al-Saeedi et al. [17]. The up-
take results were expressed as radioactivity in MBq/mg of
protein. In the control (no asiaticoside, 0) and at 10, 20,
30, 40, and 50 μM asiaticoside, the mean ± SE levels of
MIBI uptake were 0.95 ± 0.007, 0.81 ± 0.009, 0.79 ± 0.019,
0.63 ± 0.004, 0.13 ± 0.006 and 0.07 ± 0.008, respectively.
The uptake was dose dependent, and asiaticoside inhibited
47% of MIBI uptake. A significant reduction in MCF-7 cell
uptake was observed at concentrations higher than 20 μMasiaticoside.
Figure 5 Percentage of fragmented DNA in response to the effects of asiaticoside using a caspase-3 fluorescence assay. To the right of
the graph is shown a western blot for the same lysate prepared for ELISA and caspase 3 assays using MCF-7 and HaCaT cells.
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compared with the control.
MIBI tumour uptake imaging and processing
The regional distribution of MIBI uptake count in tu-
mours was determined and divided by the whole body
count in groups II, III and IV, to obtain tumour MIBI up-
take ratios. The results showed that the administration of
asiaticoside (200 μg/animal) significantly reduced tumour
MIBI uptake ratios (p = 0.026) using Student’s paired t test.
Figure 10 shows histograms of the tumour MIBI uptake
ratio for all groups expressed as the means ± SD.
Scanning electron microscopy (SEM) was performed to
investigate changes in animal groups. Preliminary results
indicated that all organs were normal, and there was noFigure 6 Histograms of DNA synthesis with 0, 20, 40 and 80 μm
asiaticoside treatment (S phase; % gated S phase cells in cell
cycle) as measured by flow cytometry.difference between them. The only differences were ob-
served for groups II, III, and IV, which showed tumours
that manifested as basal cell carcinomas. Tumours at-
tached to the skin show that most of the connective tissue
transformed into tumour cells 12 weeks post-DMBA ex-
posure upon SEM imaging (Figure 11a). The tumours were
histologically adenocarcinomas without the tendency to
develop metastases. Individual tumour cells have rounded
nuclei, moderate pleomorphism, coarse chromatin, incon-
spicuous nucleoli, a moderate amount of eosinophilic cyto-
plasm, and rare mitotic figures. Figure 11b shows tumours
with trichrome staining.
The results also showed that administration of 200 μg
asiaticoside/animal significantly reduced the percent of
tumour growth compared with the control (p = 0.001)
using Student’s paired t test. The percent of tumour
growth (mean ± SD) was as follows: 32.85 ± 2.0 in group
II, 23.30 ± 2.0 in group III and 12.85 ± 2.0 in group IV.Figure 7 Cytokinin, necrosis factor-alpha (TNF-α) and interleukin-1
beta (IL-1β) expression in DMBA-bearing tumours after asiaticoside
administration as determined by RT-PCR. C: tumours in thoracic
chest and F: femoral site.
Figure 8 Figure presenting images of breast cancer tissue used for in vivo study.
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In this study, the IC50 of asiaticoside in MCF-7 cells
was determined. In addition, the asiaticoside potential for
the cytotoxicity of hydrogen peroxide and the percentage
of fragmented DNA in MCF-7 cells was detected. Our re-
sults are in agreement with studies that have investigated
the effects of asiaticoside in MCF-7 cells [17,21]. This
finding suggests that asiaticoside stimulates the process
of programmed cell death, apoptosis, by a certain mech-
anism. For the mechanism of asiaticoside, Gurfinkel
et al. reported that disruption of the cellular endoplas-
mic reticulum and alterations in calcium homeostasis
are early events in asiaticoside-induced apoptosis [22].
Another study suggested that asiaticoside administra-
tion causes a disturbance in mitochondrial function [23]
as manifested by apoptosis [2].
Our results showed an increase in the activity of cas-
pase 3 and S phase, which is in agreement with a study
that reported the anti-tumour effects of asiaticoside involv-
ing activated caspase-3 protein. Asiaticoside plus vincristineTable 1 The means of the animal body weight and
gain ± SD during the experiment for each group in grams
Week Group I Group II Group III Group IV Group V
1 251 ± 50 250 ± 50 254 ± 50 251 ± 50 254 ± 50
3 285 ± 10 282 ± 10 284 ± 10 282 ± 10 286 ± 10
6 318 ± 10 305 ± 10 308 ± 10 302 ± 10 318 ± 10
9 349 ± 10 332 ± 10 335 ± 10 336 ± 10 350 ± 10
12 395 ± 10 379 ± 10 384 ± 10 382 ± 10 392 ± 10enhanced S-G(2)/M arrest, up-regulated cyclin B1 protein
expression, and down-regulated P34(cdc2) protein expres-
sion in KB cells [21].
Many studies have reported that the Sprague–Dawley
(SD) rat animal model can lead to promising conclusions
for chemoprevention [24-29]. In this study, we used SD
rats as our model. This study showed that DMBA induced
tumours in female SD rats beginning with the 8th week in
our experiments. This observation is in agreement with
earlier studies that have reported that the administration
of polycyclic hydrocarbon 7,12-dimethylbenz(a)anthracene
(DMBA) to female SD rats at day 50 produces primary
mammary carcinomas in all animals within 2 to 3 months
[21,30].
Tumours were observed in groups II, III, and IV in
our study. These tumours were palpable and observed
visually. In addition, histopathology using light and scan-
ning electron microscopy was performed to confirm the
development spontaneous tumour tissue and its type.
No metastasis was found in other organs. This result is in
agreement with many studies. Human breast cancer usu-
ally originates in the ductal region, and here, the DMBA-
induced mammary tumour model exhibits the same origin
[31-34].
In our study, the body weight of the rats did not show
significant differences between normal and tumour-bearing
rats, suggesting that our experimental model did not pro-
duce side-effects that could cause weight loss. In contrast,
in studies by Perumal et al. [35] and Padmavathi et al. [36],
although there was no initial significant change in body
Figure 9 Weekly animal tumour growth data (volume in mm3) for all 5 groups beginning with the 8th week of study.
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significant (p < 0.001) decrease in body weight for DMBA-
induced tumours in female SD rats at the end of the study.
In addition, our results are in agreement with studies
that have investigated the effects of Centella asiatica
(aqueous extract) and asiaticoside in protecting against
the adverse effects of radiation (gamma-irradiation). Cen-
tella asiatica rendered significant radioprotection against
radiation-induced body weight loss [37,38].
MIBI is an accurate and efficient test for the detection of
breast malignancies [39,40]. MIBI was used to determine
tumour uptake and in vivo functional imaging by normal-
ising with whole-body region counts. Asiaticoside treat-
ment reduced the tumour uptake of experimental rats.
Here, we demonstrated that after a course of asiaticoside
treatment, all rats that developed multiple mammary tu-
mours exhibited tumour regression and a reduction in
MIBI uptake. This result is in agreement with a study by
Al-Saeedi et al. [17], who demonstrated that in vitro MIBIFigure 10 Histograms of the tumour MIBI uptake ratio of all groups euptake in MCF-7 breast cancer cells was dose dependent
and that asiaticoside significantly inhibited 47% of MIBI
uptake in comparison with control. MIBI uptake signifi-
cantly decreased with increasing asiaticoside concentra-
tion. This observation suggests that asiaticoside stimulates
apoptosis by a certain mechanism. Several studies re-
ported that asiaticoside acts as a biochemical modulator,
and it may induce apoptosis or have protective effects
such as against beta-amyloid neurotoxicity [41].
MIBI is associated with mitochondrial integrity and cel-
lular viability [42]. Oxidative stress is induced in a cancer-
bearing rat, and asiaticoside may induce chemopreventive
action against cancer on a molecular mechanism basis.
Scintimammography using MIBI was proposed recently
by Khalkhali et al. [43,44] and other investigators for the
detection of breast cancer. The sensitivity in this study
was found to be up to 94% with a specificity of 88%.
Abdel-Dayem et al. [45] reviewed the intracellular up-
take of MIBI and found that in contrast with Tl-201 mxpressed as the means ± SD.
Figure 11 A histological section of developed tumour 12 weeks post-DMBA exposure, a: tumour scan using scanning electron
microscopy (SEM) imaging. b: tumour scan using trichrome staining.
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sions despite the fact that these lesions are known to have
a high rate of metabolism. These authors summarised a
few studies and found that the entry of this complex is ac-
complished by the combination of charge and lipophilicity.
The retention of MIBI, which occurs in the mitochondria,
is related to the rate of mitochondrial metabolism and its
intracellular number. Other studies reported only a few
cases with inflammatory breast changes. Palmedo et al.
[46] reported two false-positive results in three women
with benign inflammatory breast lesions. One study re-
ported the characteristics of MIBI scintimammography in
acute mastitis and found that in this pathologic condition,
MIBI tends to concentrate and accumulate in areas of ac-
tive mastitis and inflammatory breast lesions [47] but be-
comes normal after successful treatment of the infection.
Up to 20% of all cancers arise in association with chronic
inflammation and most, if not all, solid tumours contain
inflammatory infiltrates. Immune cells have a broad impact
on tumour initiation, growth and progression, and many of
these effects are mediated by proinflammatory cytokines.
Among these cytokines, the pro-tumourigenic functions of
TNF and interleukin 6 (IL-6) are well established. The role
of TNF and IL-6 as master regulators of tumour-associated
inflammation and tumourigenesis makes them attractive
targets for adjuvant treatment in cancer [48].
In this study, the results showed that the in vitro and
in vivo mRNA expression by RT-PCR after standardising
the techniques was similar. Our results reported thatasiaticoside has an effect on cytokinin expression in
DMBA-mediated tumours and MCF-7 cells. Asiaticoside
decreased the expression of tumour necrosis factor-alpha
(TNF-α), a cytokine involved in systemic inflammation
that is a member of a group of cytokines that stimulate the
acute phase reaction. The primary role of TNF lies in the
regulation of immune cells. TNF is an endogenous pyro-
gen, which is able to induce fever and apoptotic cell death
and sepsis. This protein is chiefly produced by activated
macrophages although it can be produced by other cell
types as well. In addition, the results showed that asiatico-
side decreased the expression of interleukin-1 beta (IL-1β).
IL-1β is a member of the interleukin 1 cytokine family.
This cytokine is produced by activated macrophages as a
proprotein, which is proteolytically processed to its active
form by caspase 1 (CASP1/ICE). This cytokine is an im-
portant mediator of the inflammatory response, and it is
involved in a variety of cellular activities, including cell
proliferation, differentiation, and apoptosis. Here, asiatico-
side decreased the activity of cytokines that are important
mediators of the inflammatory response and are involved
in cellular proliferation, differentiation, and apoptosis.
Our results are in agreement with many studies that
have reported that asiaticoside has anti-inflammatory ac-
tivities in several inflammatory models. Asiaticoside has
protective effects against sepsis-induced acute kidney in-
jury, which is most likely associated with the inhibition
of IL-6 in serum and the iNOS protein in kidney tissues
[49]. Asiaticoside reduced the content of IL-6 and TNF-
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[50,51].
In this study, asiaticoside suppressed proliferation, de-
creased MIBI uptake and diminished the growth rate of
in vivo 7,12 dimethyl benzanthracene (DMBA)-induced
mammary tumours in rats and in vitro MCF-7 cell uptake;
however, the mechanisms for these process remains un-
known. There are many different mechanisms through
which asiaticoside can act in cancers and other tissues.
For example, asiaticoside inhibits hypertrophic scar
fibroblast formation from the S to M phase through the
Smad signalling pathway [52]. Asiaticoside possesses
good wound-healing activities in many species, including
humans, because of its simulative effect on collagen synthe-
sis [53] and the reticuloendothelial system [54,55], which
relieves inflammation. Asiaticoside promotes apoptosis and
alters cell membranes by an unknown immune-mediated
mechanism. Overall, the results of this study showed that
the administration of asiaticoside significantly reduced the
percent of tumour growth that is significantly correlated
with MIBI uptake ratios, and this is also correlated with
caspase-3, TNF-α and IL-1β values.
Conclusion
The results of this study suggest that asiaticoside acts as
a biochemical modulator that induces apoptosis in vitro
and in vivo in MCF-7 cells and DMBA-induced rat can-
cers, respectively. Asiaticoside has potential chemopre-
ventive, antitoxic-enhancing anti-tumour activity, and
anti-inflammatory effects.
Asiaticoside significantly reduces in vitro and in vivo
tumour volumes. After a course of asiaticoside treatment,
all rats that developed multiple mammary tumours exhib-
ited tumour regression and reduction. In addition, asiati-
coside had significantly reduced the TNF-α and IL-1β
cytokinin and MIBI uptake ratios. The causes and mecha-
nisms of prevention require further investigation. Future
studies should be performed to confirm our findings and
further delineate the clinical role of asiaticoside.
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